Maxim Group Begins Coverage on Evaxion A/S (NASDAQ:EVAX)

Investment analysts at Maxim Group assumed coverage on shares of Evaxion A/S (NASDAQ:EVAX) in a research report issued on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $10.00 price target on the stock. Maxim Group’s price target would indicate a potential upside of 203.95% from the stock’s previous close.

Several other equities research analysts have also weighed in on EVAX. Edward Jones assumed coverage on Evaxion A/S in a report on Thursday, October 30th. They issued a “buy” rating and a $10.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Finally, JonesTrading upgraded shares of Evaxion A/S to a “strong-buy” rating in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.75.

Evaxion A/S Trading Down 5.5%

NASDAQ:EVAX opened at $3.29 on Thursday. Evaxion A/S has a 12 month low of $1.20 and a 12 month high of $12.15. The firm’s 50 day moving average is $4.31 and its 200 day moving average is $4.58. The stock has a market capitalization of $27.44 million, a PE ratio of -8.44 and a beta of 0.29.

Institutional Investors Weigh In On Evaxion A/S

A number of institutional investors and hedge funds have recently bought and sold shares of EVAX. SmartHarvest Portfolios LLC purchased a new stake in shares of Evaxion A/S during the 4th quarter valued at $72,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Evaxion A/S during the fourth quarter valued at about $38,000. Finally, Wesbanco Bank Inc. bought a new stake in Evaxion A/S during the fourth quarter worth about $48,000. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.